UK markets closed

Roche Holding AG (RHHBY)

OTC Markets OTCQX - OTC Markets OTCQX Delayed price. Currency in USD
Add to watchlist
35.55+0.32 (+0.91%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close35.23
Open35.33
Bid35.55 x 309400
Ask35.57 x 40000
Day's range35.29 - 35.60
52-week range29.20 - 40.15
Volume611,190
Avg. volume3,204,987
Market cap228.518B
Beta (5Y monthly)0.16
PE ratio (TTM)17.60
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.35 (3.79%)
Ex-dividend date14 Mar 2024
1y target estN/A
  • GlobeNewswire

    Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma

    The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is the first clinically approved in-situ hybridisation (ISH) test with the sensitivity to assess the full spectrum of B-cell lymphoma subtypes.1,2The test helps differentiate a B-cell cancer from a normal, reactive immune response, providing diagnostic certainty for healthcare providers and their patients. B-cell lymphoma accounts for approximately 85 percent of non-Hodgkin lymphoma (NHL) cases, which is the tenth most common cancer

  • PR Newswire

    Roche receives FDA clearance on its digital pathology solution for diagnostic use

    Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its whole-slide imaging system, the Roche Digital Pathology Dx (VENTANA DP 200), has received 510(k) clearance from the United States Food and Drug Administration (FDA). The system is intended to aid the pathologist in reviewing and interpreting digital images of scanned pathology slides to help diagnose patients.

  • GlobeNewswire

    Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

    The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi plus chemotherapy1 This Columvi combination could provide a much-needed off-the-shelf treatment option for people with transplant-ineligible R/R DLBCLData were featured in the congress Press Briefing and presented today in the Plenary Abstracts Session at EHA 2024 as a late-breaking oral presentatio